A splice‐switching antisense oligonucleotide targeting APP reduces accumulation of α‐synuclein in a mouse model of Parkinson's disease
APP-targeting SSO reduces α-syn and P-Syn in α-syn-tg mice.APP SSO lowers APP CTFs, linking APP processing to α-syn pathology.Neuronal loss in the hippocampal CA3 region is restored following APP SSO treatment.Behavioral assessments show no significant changes in female α-syn-tg mice.Findings support APP modulation as a potential strategy for synucleinopathies.
Authors
- Robert A. Rissman (ORCID: https://orcid.org/0000-0001-9245-8278)
- Bryan C. Quach (ORCID: https://orcid.org/0000-0002-1094-3104)
- Sahar Salehi (ORCID: https://orcid.org/0009-0005-2968-8077)
- Rijwan Uddin Ahammad
- Brian Spencer (ORCID: https://orcid.org/0000-0002-7486-1941)
Institutions
- University of Southern California (US)
Publication Details
- Journal
- Alzheimer s & Dementia Translational Research & Clinical Interventions
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1002/trc2.70117
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health